The prognostic relevance of FLT3 D835/I836 mutations (FLT3-TKD) in cytogenetically normal acute myeloid leukemia (CN-AML) remains to be established. After excluding patients with 
Introduction
The fms-related tyrosine kinase 3 gene (FLT3) encodes a protein member of the type III plateletderived growth factor family of receptor tyrosine kinases that play an important role in normal involving other amino acid residues include the Y842C, 3 K663Q 4 and V592A 5 and those occurring in the juxtamembrane domain. 6 The proteins coded by the FLT3-ITD and FLT3-TKD mutations exhibit ligand-independent FLT3 dimerization and constitutive activation through autophosphorylation. Although both FLT3-ITD and FLT3-TKD mutations are transforming in in vitro models, several lines of evidence indicate that these two types of mutations influence downstream signal transduction pathways differently. [7] [8] [9] While the adverse clinical impact of the presence of FLT3-ITD in adults under the age of 60 years with CN-AML is well established, 2,10-16 the prognostic significance of FLT3-TKD remains to be elucidated. 13, [17] [18] [19] Here, we assessed the prognostic impact of FLT3-TKD, specifically D835/I836 mutations, in younger adults with de novo CN-AML lacking FLT3-ITD and treated on similar Cancer and Leukemia Group B (CALGB) frontline treatment protocols for AML (9621 and 19808) . We show that the presence of FLT3-TKD is associated with worse diseaseFor personal use only. on April 14, 2017. by guest www.bloodjournal.org From free survival (DFS) relative to similar patients with wild-type FLT3 alleles (FLT3-WT). We also report the first Affymetrix microarray-derived gene-expression signature differentiating FLT3-TKD+ from FLT3-WT CN-AML, that includes genes with potential biological and therapeutic relevance.
Materials and Methods

Patients
Pretreatment bone marrow (BM) or blood samples were obtained from adult patients with de novo CN-AML, younger than 60 years and treated on similar protocols either CALGB 9621 20 or CALGB 19808. 21 All patients gave The Ohio State University Institutional Review Boardapproved informed consent for the procurement and research use of their samples. CALGB 9621 evaluated variable doses of daunorubicin and etoposide in combination with fixed doses of cytarabine (100 mg/m 2 ) without (ADE) or with (ADEP) PSC-833, a multi-drug resistance protein inhibitor, also called valspodar. 20 Based on the results of CALGB 9621, patients were treated on CALGB 19808 with fixed doses of daunorubicin (90 mg/m 2 ) and etoposide (100 mg/m 2 ) in ADE, or daunorubicin (40 mg/m 2 ) and etoposide (40 mg/m 2 ) in ADEP. 21 Upon achievement of complete remission (CR), patients were assigned to intensification with highdose cytarabine and etoposide for stem cell mobilization followed by myeloablative treatment with busulfan and etoposide supported by autologous peripheral blood stem cell transplantation (APSCT). Patients unable to receive APSCT received two additional cycles of high-dose cytarabine. There were no significant differences in CR rates, OS, or DFS among patients with CN-AML between these two protocols.
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From Pretreatment cytogenetic analyses of BM were performed by CALGB-approved institutional cytogenetic laboratories as part of CALGB 8461, a prospective cytogenetic companion, and were centrally reviewed, as previously reported. 22 To be considered cytogenetically normal, at least 20 BM metaphase cells were analyzed and the karyotype found to be normal in each case.
To detect the presence or absence of FLT3-TKD as previously described, 15,23 RNA was extracted from thawed, pretreatment, cryopreserved cells (Trizol Reagent, Invitrogen, Carlsbad, CA) and cDNA prepared using Superscript II and random hexamer primers (Invitrogen, Carlsbad, CA).
Following PCR, aliquots were subjected to enzymatic digestion with EcoRV and size fractionation through 1.25% agarose gels. Quantification of FLT3-TKD mutant alleles determined as a percentage of total FLT3 alleles was carried out as described previously. 
Statistical Methods
Associations between patients with and without FLT3-TKD and baseline demographic, clinical and molecular features were described using Fisher's exact and Wilcoxon rank sum tests for categorical and continuous variables, respectively. CR required an absolute neutrophil count ≥ 1,500/µl, a platelet count ≥ 100,000/µl, no leukemic blasts in the blood, BM cellularity >20% with maturation of all cell lines, no Auer rods, <5% BM blast cells, and no evidence of extramedullary leukemia, with persistence for at least one month. Relapse was defined by ≥ 5% BM blasts, circulating leukemic blasts or development of extramedullary leukemia. DFS was measured from the date of CR until date of relapse, censoring for patients alive and relapse-free at last follow-up. Overall survival (OS) was measured from the date on study until the date of death, where patients alive at last follow-up were censored. Median follow-up for patients who achieved a CR and were alive and relapse-free was 5.2 years (range, 1.5-8.8 years).
Median follow-up for those alive was 4.6 years (range, 1.3-8.9 years). Estimated probabilities of DFS and OS were calculated using the Kaplan-Meier method, and the log-rank test evaluated differences between survival distributions. The proportional hazards model was used to evaluate the impact of FLT3-TKD on DFS using a limited backwards selection procedure. Variables considered for the multivariable analysis included age, sex, race, hemoglobin, platelet and white blood cell (WBC) counts, percentages of blood and BM blasts, extramedullary involvement, MAPPFinder uses a permutation procedure to determine the overrepresented gene ontologies.
MLL-PTD
All analyses were performed by the CALGB Statistical Center. 
Clinical outcomes
No differences were observed between FLT3-WT and FLT3-TKD+ patients with respect to induction and consolidation treatments received on the two CALGB studies (Table 1 ). All patients with FLT3-TKD and 85% of patients with FLT3-WT achieved a CR (P=.13; Table 1 ).
FLT3-TKD+ patients had significantly shorter DFS than FLT3-WT patients (P=.01). The
estimated DFS rates at 3 years for the FLT3-TKD+ and FLT3-WT groups were 31% and 60%, respectively (Table 1, Figure 1 ). FLT3-TKD+ patients also tended to have worse OS, although the difference was not statistically significant (P=.17). The estimated OS rates at 3 years for the FLT3-TKD+ and FLT3-WT groups were 40% and 65%, respectively (Table 1) .
In a multivariable analysis, the presence of a FLT3-TKD remained significantly associated with worse DFS (P=.02, Figure S1B ). There was only one patient with both FLT3-TKD and high
BAALC expression who relapsed within 9 months from achieving CR and died shortly thereafter, and therefore the impact of FLT3-TKD on high BAALC expressers could not be evaluated. With regard to ERG expression, patients with FLT3-TKD tended to have worse DFS than those without among both low and high ERG expressers, although no large differences were observed ( Figure S1C ). Six of the eight patients with 100% of mutant alleles relapsed compared with three of the six patients with less than 100% of mutant alleles; in both groups, one-half of the patients died.
A gene-expression signature differentiating FLT3-TKD and FLT3-WT CN-AML
Gene-expression microarray analysis was performed on patient samples for which sufficient RNA material was available. We identified a signature consisting of 333 probe sets differentially expressed (P<.001) between FLT3-TKD+ and FLT3-WT patients ( Figure 2 and Table S1 ). Of (Tables 3 and S1 ). Among the 31 genes underexpressed in FLT3-TKD patients with 2.0-fold or higher expression in FLT3-WT patients were MPO; RHOH, a negative regulator of signal transduction; and MLLT3 (also known as AF9), a transcription factor involved in t(9;11)(p22;q23), a recurrent translocation in AML (Tables 3 and S1 (Table S1 ).
Gene ontologies associated with the FLT3-TKD signature
To gain further insight into the biological importance of the gene-expression signature and uncover functional patterns associated with FLT3-TKD, we identified overrepresented gene ontology (GO) terms among the 215 known genes that comprised the expression signature.
Thirty-two GO terms (P≤.005) were enriched among the 103 genes overexpressed in FLT3-TKD patients ( Figure S2 ). These included terms related to the cellular membrane ( Figure S2A ) and to transmembrane transport (eg, symporter activity and monocarboxylic acid transporter activity) 35 In an analysis restricted to CN-AML patients, Mead et al. 35 observed a trend for FLT3-TKD+ patients to have longer OS. Reasons for the outcome differences among CN-AML patients related to FLT3-TKD in our study and the aforementioned MRC study 35 comprise, but are likely not limited to, sampling variability, the fact that in the Mead et al. 35 study, OS of CN-AML patients was evaluated comparing FLT3- 
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Additionally, Mead et al. 35 reported that a higher percentage of FLT3-TKD mutations contributed to a better cumulative index of relapse and OS when compared with patients with a lower percentage of FLT3-TKD mutations. 35 However, in the 14 CALGB samples for which DNA was available to perform the fluorescence-based quantification assay, we observed no differences in DFS or OS between patients having high or low FLT3-TKD percentages.
We also gained insights into the biologic mechanisms potentially underlying CN-AML with TKD associated AML, our data would suggest that a thorough investigation of the optimal timing of JNK inhibitors with or without cytarabine would be needed.
In conclusion, this study shows that for younger adults with de novo CN-AML lacking FLT3- and red expression above the median value for the given probe set. For display purposes, the expression values of the probe sets were centered so that each probe set has the same median expression value. Rows represent probe sets (see Table S2 for identification of probe sets) and columns represent patients. Patients are grouped by FLT3-TKD (+) and FLT3-WT (-) status.
NPM1 status is indicated as mutation positive (M) or wild-type (WT).
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